<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344719</url>
  </required_header>
  <id_info>
    <org_study_id>2010-020880-19</org_study_id>
    <nct_id>NCT02344719</nct_id>
  </id_info>
  <brief_title>Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis</brief_title>
  <official_title>The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to analyze the effect of Taurin on portal hemodynamics in patients
      with advanced liver cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      28 days of 6 grams Taurine versus Placebo (randomization 1:1).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HVPG change in mmHg after 28 days with Taurin 6g or placebo</measure>
    <time_frame>28 days</time_frame>
    <description>To investigate the response to 6g taurine p.o. for 28 days on the hepatic venous pressure gradient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>6 capsules Taurin per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 capsuless placebo per day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurin 6g per day per oral for 28 days</intervention_name>
    <description>Taurin 6g per day per oral for 28 days</description>
    <arm_group_label>6 capsules Taurin per day</arm_group_label>
    <other_name>Taurin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG Measurement baseline</intervention_name>
    <description>On day 1 (baseline) and day 28 HVPG measurement will be performed</description>
    <arm_group_label>6 capsules Taurin per day</arm_group_label>
    <arm_group_label>6 capsuless placebo per day</arm_group_label>
    <other_name>HVPG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG Measurement day 28</intervention_name>
    <description>On day 1 (baseline) and day 28 HVPG measurement will be performed</description>
    <arm_group_label>6 capsules Taurin per day</arm_group_label>
    <arm_group_label>6 capsuless placebo per day</arm_group_label>
    <other_name>HVPG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 6g per day per oral for 28 days</intervention_name>
    <description>Placebo to Taurin 6g per day per oral for 28 days</description>
    <arm_group_label>6 capsuless placebo per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male and female) aged older than 18 years with advanced liver cirrhosis
             (Child's Grade B and Child's Grade C), regardless of the disease origin (viral,
             alcoholic, idiopathic), who are scheduled for hepatic hemodynamic investigation

          -  Negative pregnancy test of women with childbearing potential

          -  Patient without beta blocker therapy: due to: intolerance of the medication,
             preexisting contraindication against beta blocker therapy, endoscopic band ligation as
             prophylaxis

        Exclusion Criteria:

          -  History of variceal bleeding without endoscopic band ligation

          -  History of endoscopically diagnosed large varices with red spots without previous
             bleeding and without endoscopic band ligation

          -  HVPG &lt; 10 mmHg

          -  HVPG &gt; 20 mmHg and varices, unless ligated and treated in an eradication program
             within 6 months

          -  Beta Blocker therapy

          -  History of hypersensitivity to the trial drugs and contrast agent or to drugs with
             similar chemical structure

          -  Treatment with vasoactive or non-steroidal anti-inflammatory drugs or systematic
             antibiotics one week before the study

          -  Exclusion criteria for hepatic hemodynamic investigation

          -  Cardiac, renal or respiratory failure

          -  Previous surgical or transjugular intrahepatic portosystemic shunt

          -  Breast-feeding or pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Arnulf Ferlitsch, MD</investigator_full_name>
    <investigator_title>Assoz. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>taurin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

